Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Update

Entera Bio Ltd. (NASDAQ:ENTX) was the target of a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 95,800 shares, a growth of 102.5% from the December 31st total of 47,300 shares. Based on an average trading volume of 132,000 shares, the short-interest ratio is presently 0.7 days.

Hedge Funds Weigh In On Entera Bio

A number of large investors have recently bought and sold shares of ENTX. Signature Estate & Investment Advisors LLC bought a new stake in shares of Entera Bio during the third quarter worth $90,000. Perigon Wealth Management LLC purchased a new position in Entera Bio in the 4th quarter worth about $325,000. Finally, Parkman Healthcare Partners LLC lifted its holdings in Entera Bio by 2.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock valued at $781,000 after buying an additional 9,558 shares in the last quarter. Hedge funds and other institutional investors own 14.11% of the company’s stock.

Entera Bio Price Performance

Shares of NASDAQ:ENTX traded down $0.14 during trading hours on Friday, hitting $2.19. 55,144 shares of the company’s stock traded hands, compared to its average volume of 225,967. The firm has a market capitalization of $78.36 million, a P/E ratio of -8.42 and a beta of 1.49. The business has a fifty day moving average price of $2.18 and a 200-day moving average price of $1.92. Entera Bio has a 1 year low of $0.68 and a 1 year high of $3.35.

Analyst Ratings Changes

Separately, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Entera Bio in a report on Monday, November 11th.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.